HMGB1 exacerbates experimental mouse colitis by enhancing innate lymphoid cells 3 inflammatory responses via promoted IL-23 production

Innate Immunity

Volumn 22, Issue 8, 2016, Pages 696-705

  Chen, Xiangyu ^a   Li, Lingyun ^a   Khan, Muhammad Noman ^b   Shi, Lifeng ^a   Wang, Zhongyan ^a   Zheng, Fang ^a   Gong, Feili ^a   Fang, Min ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

high mobility group box 1; Inflammatory bowel disease; innate lymphoid cell; Toll like receptor 2; Toll like receptor 4

Indexed keywords

ANTIINFLAMMATORY AGENT; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 7 RECEPTOR; THY 1 ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; TLR2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; HISTOPATHOLOGY; INFLAMMATION; LAMINA PROPRIA; LYMPHOID CELL; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; COLON; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; KNOCKOUT MOUSE; LYMPHOCYTE; METABOLISM;

ANIMALS; ANTIBODIES, BLOCKING; CELLS, CULTURED; COLITIS; COLON; DENDRITIC CELLS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84992053048     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425916669862     Document Type: Article

References (41)

1. Baumgart DC, Sandborn WJ,. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
2. Fonseca-Camarillo G, Yamamoto-Furusho JK,. Immunoregulatory pathways involved in inflammatory bowel disease. Inflamm Bowel Dis 2015; 21: 2188-2193.
3. Ng SC,. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol (N Y) 2016; 12: 193-196.
4. Harris HE, Andersson U, Pisetsky DS,. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8: 195-202.
5. Scaffidi P, Misteli T, Bianchi ME,. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
6. Schaper F, Westra J, Bijl M,. Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus. Mol Med 2014; 20: 72-79.
7. Chen Y, Sun W, Gao R, et al. The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology 2013; 52: 1739-1747.
8. Liu QY, Yao YM,. Inflammatory response and immune regulation of high mobility group box-1 protein in treatment of sepsis. World J Emerg Med 2010; 1: 93-98.
9. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377.
10. Mudaliar H, Pollock C, Ma J, et al. The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PloS One 2014; 9: e108844-e108844.
11. Bank S, Skytt Andersen P, Burisch J, et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PloS One 2014; 9: e98815-e98815.
12. Cheng Y, Zhu Y, Huang X, et al. Association between TLR2 and TLR4 gene polymorphisms and the susceptibility to inflammatory bowel disease: A meta-analysis. PloS One 2015; 10: e0126803-e0126803.
13. Feng J, Guo C, Zhu Y, et al. Baicalin down regulates the expression of TLR4 and NFkB-p65 in colon tissue in mice with colitis induced by dextran sulfate sodium. Int J Clin Exp Med 2014; 7: 4063-4072.
14. Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2029-2040.
15. Yang R, Miki K, Oksala N, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol 2009; 297: R362-R369.
16. Fuchs A, Colonna M,. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. Curr Opin Gastroenterol 2013; 29: 581-587.
17. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149.
18. Klose CS, Flach M, Möhle L, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014; 157: 340-356.
19. Hoyler T, Klose CS, Souabni A, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012; 37: 634-648.
20. Killig M, Glatzer T, Romagnani C,. Recognition strategies of group 3 innate lymphoid cells. Front Immunol 2014; 5: 142-142.
21. Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009; 206: 35-41.
22. Sawa S, Cherrier M, Lochner M, et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science 2010; 330: 665-669.
23. Basu R, O'Quinn DB, Silberger DJ, et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012; 37: 1061-1075.
24. Walker JA, Barlow JL, McKenzie ANJ,. Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013; 13: 75-87.
25. Geremia A, Arancibia-Cárcamo CV, Fleming MPP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208: 1127-1133.
26. Buonocore S, Ahern PP, Uhlig HH, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464: 1371-1375.
27. Cox JH, Kljavin NM, Ota N, et al. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol 2012; 5: 99-109.
28. Zou H, Yang Y, Gao M, et al. HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs. Am J Transplant 2014; 14: 1765-1777.
29. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance. J Immunol 1996; 157: 2174-2185.
30. Maeda S, Hikiba Y, Shibata W, et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 2007; 360: 394-400.
31. Goc J, Hepworth MR, Sonnenberg GF,. Group 3 innate lymphoid cells: Regulating host-commensal bacteria interactions in inflammation and cancer. Int Immunol 2016; 28: 43-52.
32. Fan Y, Liu B,. Expression of Toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med 2015; 9: 1455-1459.
33. Crellin NK, Trifari S, Kaplan CD, et al. Regulation of cytokine secretion in human CD127(+) LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 2010; 33: 752-764.
34. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
35. Dave SH, Tilstra JS, Matsuoka K, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86: 633-643.
36. Sappington PL, Yang R, Yang H, et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123: 790-802.
37. Palone F, Vitali R, Cucchiara S, et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 1448-1457.
38. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med 2014; 40: 1-116.
39. Seiderer J, Brand S,. IL-22: A two-headed cytokine in IBD? Inflamm Bowel Dis 2009; 15: 473-474.
40. Kirchberger S, Royston DJ, Boulard O, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210: 917-931.
41. Eken A, Singh AK, Oukka M,. Interleukin 23 in Crohn's disease. Inflamm Bowel Dis 2014; 20: 587-595.